Active, not recruitingPhase 2NCT01142388
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Steven J CohenECOG-ACRIN Cancer Research Group
- Intervention
- Cixutumumab(biological)
- Enrollment
- 94 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2026
Study locations (30)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- The Medical Center of Aurora, Aurora, Colorado, United States
- Boulder Community Foothills Hospital, Boulder, Colorado, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- AdventHealth Porter, Denver, Colorado, United States
- Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- Western States Cancer Research NCORP, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
- Banner North Colorado Medical Center, Greeley, Colorado, United States
- Saint Anthony Hospital, Lakewood, Colorado, United States
- AdventHealth Littleton, Littleton, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01142388 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →